Drotrecogin alfa (activated) should not be used in patients with severe sepsis and low risk for death: Commentary

Critical Care

Volumn 10, Issue 6, 2006, Pages

  Gupta, Sanjay ^a   Milbrandt, Eric B ^a   Chelluri, Lakshmipathi ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DROTRECOGIN; HEPARIN;

BLEEDING; CLINICAL TRIAL; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG RESPONSE; EARLY INTERVENTION; HIGH RISK PATIENT; HUMAN; INTENSIVE CARE; LOW DRUG DOSE; MORTALITY; PRIORITY JOURNAL; SEPSIS; SHORT SURVEY;

EID: 34447631200     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc5071     Document Type: Short Survey

References (10)

1. Abraham E Laterre PF Garg R Levy H Talwar D Trzaskoma BL Francois B Guy JS Bruckmann M Rea-Neto A Rossaint R Perrotin D Sablotzki A Arkins N Utterback BG Macias WL Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death N Engl J Med 2005 353 1332-1341 10.1056/NEJMoa050935 16192478
2. Dhainaut JF Yan SB Margolis BD Lorente JA Russell JA Freebairn RC Spapen HD Riess H Basson B Johnson G III Kinasewitz GT Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis Thromb Haemost 2003 90 642-653 14515185
3. Siegel JP Assessing the use of activated protein C in the treatment of severe sepsis N Engl J Med 2002 347 1030-1034 10.1056/NEJMsb021512 12324563
4. Baillie JK Murray G Drotrecogin alfa (activated) in severe sepsis N Engl J Med 2006 354 94-96 10.1056/NEJMc052759 16395834
5. Friedrich JO Drotrecogin alfa (activated) in severe sepsis N Engl J Med 2006 354 94-96 10.1056/NEJMc052759 16394311
6. LaRosa SP Drotrecogin alfa (activated) in severe sepsis N Engl J Med 2006 354 94-96 10.1056/NEJMc052759 16395833
7. Dellinger RP Carlet JM Masur H Gerlach H Calandra T Cohen J Gea-Banacloche J Keh D Marshall JC Parker MM Ramsay G Zimmerman JL Vincent JL Levy MM Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock Intensive Care Med 2004 30 536-555 10.1007/s00134-004-2398-y 14997291
8. Rivers E Nguyen B Havstad S Ressler J Muzzin A Knoblich B Peterson E Tomlanovich M Early goal-directed therapy in the treatment of severe sepsis and septic shock N Engl J Med 2001 345 1368-1377 10.1056/ NEJMoa010307 11794169
9. Vincent JL Bernard GR Beale R Doig C Putensen C Dhainaut JF Artigas A Fumagalli R Macias W Wright T Wong K Sundin DP Turlo MA Janes J Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment Crit Care Med 2005 33 2266-2277 10.1097/ 01.CCM.0000181729.46010.83 16215381
10. Wheeler A Steinbrug J Linde-Zwirble W Shwed J Zeckel M Results of MERCURY, a retrospective multicenter observational study [abstract]. Presented at 33rd Critical Care Congress, Orlando, 2004 Crit Care Med 2003 31 A120